Akèy › Kansè poumon selil ti › Texas › Houston
Etid klinik pou Kansè poumon selil ti nan Houston, TX
26 etid pou Kansè poumon selil ti ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center /ID# 277929, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Ap rekriteFaz 2/3
- Texas Oncology - Gulf Coast, Houston
- Texas Oncology - Gulf Coast, Houston
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Ap rekriteFaz 3
- The University of Texas MD Anderson Cancer Center /ID# 280070, Houston
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Ap rekriteFaz 1/2
- Next Oncology - Houston, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Site 1005, Houston
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Houston
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Ap rekriteFaz 3
- The University of Texas MD Anderson Cancer Center, Houston
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center Uni of Te, Houston
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Ap rekriteFaz 3
- Houston Methodist Cancer Center, Houston
- University of Texas Md Anderson Cancer Center, Houston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
- Oncology Consultants, PA- Houston, Houston
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
Ap rekriteFaz 1/2
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
Ap rekriteFaz 1
- Zelgen Site 106, Houston
Etid Kansè poumon selil ti nan lòt vil
- Arlington, VA23 etid
- New York City, NY22 etid
- Boston, MA21 etid
- Nashville, TN20 etid
- Los Angeles, CA20 etid
- Orlando, FL15 etid
- Dallas, TX13 etid
- Cleveland, OH13 etid
- Chicago, IL13 etid
- St. Louis, MO13 etid
- Detroit, MI12 etid
- Washington, DC12 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.